DK2735568T3 - Oligonukleotidanaloger med kationiske bindinger mellem underenheder - Google Patents

Oligonukleotidanaloger med kationiske bindinger mellem underenheder

Info

Publication number
DK2735568T3
DK2735568T3 DK13186973.7T DK13186973T DK2735568T3 DK 2735568 T3 DK2735568 T3 DK 2735568T3 DK 13186973 T DK13186973 T DK 13186973T DK 2735568 T3 DK2735568 T3 DK 2735568T3
Authority
DK
Denmark
Prior art keywords
bindings
cationic
sub
units
oligonucleotide analysis
Prior art date
Application number
DK13186973.7T
Other languages
English (en)
Inventor
Dwight D Weller
Jed N Hassinger
Bao Cai
Original Assignee
Sarepta Therapeutics Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from US11/432,155 external-priority patent/US20070037763A1/en
Priority claimed from US11/431,968 external-priority patent/US8785407B2/en
Priority claimed from US11/432,031 external-priority patent/US8084433B2/en
Priority claimed from US11/432,216 external-priority patent/US7625873B2/en
Priority claimed from US11/433,214 external-priority patent/US8067569B2/en
Priority claimed from US11/433,213 external-priority patent/US20070004661A1/en
Priority claimed from US11/433,840 external-priority patent/US7507196B2/en
Priority claimed from US11/433,033 external-priority patent/US8415313B2/en
Priority claimed from US11/433,724 external-priority patent/US7888012B2/en
Priority claimed from US11/433,257 external-priority patent/US20070037764A1/en
Priority claimed from US11/518,058 external-priority patent/US8329668B2/en
Priority claimed from US11/517,757 external-priority patent/US8524676B2/en
Priority claimed from US11/595,161 external-priority patent/US20070111962A1/en
Priority claimed from US11/715,572 external-priority patent/US7582615B2/en
Application filed by Sarepta Therapeutics Inc filed Critical Sarepta Therapeutics Inc
Publication of DK2735568T3 publication Critical patent/DK2735568T3/da
Application granted granted Critical

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07H—SUGARS; DERIVATIVES THEREOF; NUCLEOSIDES; NUCLEOTIDES; NUCLEIC ACIDS
    • C07H21/00—Compounds containing two or more mononucleotide units having separate phosphate or polyphosphate groups linked by saccharide radicals of nucleoside groups, e.g. nucleic acids
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
    • C12N15/111—General methods applicable to biologically active non-coding nucleic acids
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
    • C12N15/113—Non-coding nucleic acids modulating the expression of genes, e.g. antisense oligonucleotides; Antisense DNA or RNA; Triplex- forming oligonucleotides; Catalytic nucleic acids, e.g. ribozymes; Nucleic acids used in co-suppression or gene silencing
    • C12N15/1131—Non-coding nucleic acids modulating the expression of genes, e.g. antisense oligonucleotides; Antisense DNA or RNA; Triplex- forming oligonucleotides; Catalytic nucleic acids, e.g. ribozymes; Nucleic acids used in co-suppression or gene silencing against viruses
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
    • C12N15/113—Non-coding nucleic acids modulating the expression of genes, e.g. antisense oligonucleotides; Antisense DNA or RNA; Triplex- forming oligonucleotides; Catalytic nucleic acids, e.g. ribozymes; Nucleic acids used in co-suppression or gene silencing
    • C12N15/1131—Non-coding nucleic acids modulating the expression of genes, e.g. antisense oligonucleotides; Antisense DNA or RNA; Triplex- forming oligonucleotides; Catalytic nucleic acids, e.g. ribozymes; Nucleic acids used in co-suppression or gene silencing against viruses
    • C12N15/1132—Non-coding nucleic acids modulating the expression of genes, e.g. antisense oligonucleotides; Antisense DNA or RNA; Triplex- forming oligonucleotides; Catalytic nucleic acids, e.g. ribozymes; Nucleic acids used in co-suppression or gene silencing against viruses against retroviridae, e.g. HIV
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
    • C12N15/113—Non-coding nucleic acids modulating the expression of genes, e.g. antisense oligonucleotides; Antisense DNA or RNA; Triplex- forming oligonucleotides; Catalytic nucleic acids, e.g. ribozymes; Nucleic acids used in co-suppression or gene silencing
    • C12N15/1135—Non-coding nucleic acids modulating the expression of genes, e.g. antisense oligonucleotides; Antisense DNA or RNA; Triplex- forming oligonucleotides; Catalytic nucleic acids, e.g. ribozymes; Nucleic acids used in co-suppression or gene silencing against oncogenes or tumor suppressor genes
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
    • C12N15/113—Non-coding nucleic acids modulating the expression of genes, e.g. antisense oligonucleotides; Antisense DNA or RNA; Triplex- forming oligonucleotides; Catalytic nucleic acids, e.g. ribozymes; Nucleic acids used in co-suppression or gene silencing
    • C12N15/1137—Non-coding nucleic acids modulating the expression of genes, e.g. antisense oligonucleotides; Antisense DNA or RNA; Triplex- forming oligonucleotides; Catalytic nucleic acids, e.g. ribozymes; Nucleic acids used in co-suppression or gene silencing against enzymes
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
    • C12N15/113—Non-coding nucleic acids modulating the expression of genes, e.g. antisense oligonucleotides; Antisense DNA or RNA; Triplex- forming oligonucleotides; Catalytic nucleic acids, e.g. ribozymes; Nucleic acids used in co-suppression or gene silencing
    • C12N15/1138—Non-coding nucleic acids modulating the expression of genes, e.g. antisense oligonucleotides; Antisense DNA or RNA; Triplex- forming oligonucleotides; Catalytic nucleic acids, e.g. ribozymes; Nucleic acids used in co-suppression or gene silencing against receptors or cell surface proteins
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2310/00—Structure or type of the nucleic acid
    • C12N2310/30—Chemical structure
    • C12N2310/31—Chemical structure of the backbone
    • C12N2310/314—Phosphoramidates
    • C12N2310/3145—Phosphoramidates with the nitrogen in 3' or 5'-position
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2310/00—Structure or type of the nucleic acid
    • C12N2310/30—Chemical structure
    • C12N2310/32—Chemical structure of the sugar
    • C12N2310/323—Chemical structure of the sugar modified ring structure
    • C12N2310/3233—Morpholino-type ring
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2310/00—Structure or type of the nucleic acid
    • C12N2310/30—Chemical structure
    • C12N2310/35—Nature of the modification
    • C12N2310/351—Conjugate
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2310/00—Structure or type of the nucleic acid
    • C12N2310/30—Chemical structure
    • C12N2310/35—Nature of the modification
    • C12N2310/351—Conjugate
    • C12N2310/3513—Protein; Peptide
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2320/00—Applications; Uses
    • C12N2320/50—Methods for regulating/modulating their activity
    • C12N2320/51—Methods for regulating/modulating their activity modulating the chemical stability, e.g. nuclease-resistance
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2330/00—Production
    • C12N2330/30—Production chemically synthesised
DK13186973.7T 2006-05-10 2007-05-10 Oligonukleotidanaloger med kationiske bindinger mellem underenheder DK2735568T3 (da)

Applications Claiming Priority (19)

Application Number Priority Date Filing Date Title
US11/432,216 US7625873B2 (en) 2004-07-02 2006-05-10 Antisense antibacterial method and compound
US11/432,155 US20070037763A1 (en) 2003-12-24 2006-05-10 Oligonucleotide compound and method for treating nidovirus infections
US11/432,031 US8084433B2 (en) 2004-09-16 2006-05-10 Antisense antiviral compound and method for treating ssRNA viral infection
US11/431,968 US8785407B2 (en) 2006-05-10 2006-05-10 Antisense antiviral agent and method for treating ssRNA viral infection
US80007606P 2006-05-11 2006-05-11
US80014506P 2006-05-11 2006-05-11
US80012006P 2006-05-11 2006-05-11
US79997606P 2006-05-11 2006-05-11
US11/433,213 US20070004661A1 (en) 2004-10-26 2006-05-11 Antisense antiviral compound and method for treating influenza viral infection
US11/433,214 US8067569B2 (en) 2000-05-04 2006-05-11 Splice-region antisense composition and method
US11/433,840 US7507196B2 (en) 2004-11-01 2006-05-11 Antisense antiviral compounds and methods for treating a filovirus infection
US11/433,033 US8415313B2 (en) 2004-01-23 2006-05-11 Antisense oligomers and methods for inducing immune tolerance and immunosuppression
US11/433,724 US7888012B2 (en) 2005-02-09 2006-05-11 Antisense composition and method for treating muscle atrophy
US11/433,257 US20070037764A1 (en) 2003-10-23 2006-05-11 Method and antisense composition for selective inhibition of HIV infection in hematopoietic cells
US11/518,058 US8329668B2 (en) 2005-09-08 2006-09-08 Antisense antiviral compound and method for treating picornavirus infection
US11/517,757 US8524676B2 (en) 2005-09-08 2006-09-08 Method for treating enterovirus or rhinovirus infection using antisense antiviral compounds
US11/595,161 US20070111962A1 (en) 2005-11-08 2006-11-08 Immunosuppression compound and treatment method
US11/715,572 US7582615B2 (en) 2006-03-07 2007-03-07 Antisense antiviral compound and method for treating arenavirus infection
EP07861308.0A EP2024499B1 (en) 2006-05-10 2007-05-10 Oligonucleotide analogs having cationic intersubunit linkages

Publications (1)

Publication Number Publication Date
DK2735568T3 true DK2735568T3 (da) 2017-11-13

Family

ID=40134113

Family Applications (2)

Application Number Title Priority Date Filing Date
DK07861308.0T DK2024499T3 (da) 2006-05-10 2007-05-10 Oligonukleotidanaloger med kationiske intersubunit-koblinger
DK13186973.7T DK2735568T3 (da) 2006-05-10 2007-05-10 Oligonukleotidanaloger med kationiske bindinger mellem underenheder

Family Applications Before (1)

Application Number Title Priority Date Filing Date
DK07861308.0T DK2024499T3 (da) 2006-05-10 2007-05-10 Oligonukleotidanaloger med kationiske intersubunit-koblinger

Country Status (15)

Country Link
US (1) US7943762B2 (da)
EP (2) EP2024499B1 (da)
JP (1) JP2010505741A (da)
AU (1) AU2007297861A1 (da)
CA (1) CA2651881A1 (da)
CY (2) CY1120409T1 (da)
DK (2) DK2024499T3 (da)
ES (2) ES2645410T3 (da)
HK (1) HK1198388A1 (da)
HU (2) HUE036995T2 (da)
LT (2) LT2735568T (da)
PL (1) PL2735568T3 (da)
PT (1) PT2735568T (da)
SI (2) SI2024499T1 (da)
WO (1) WO2008036127A2 (da)

Families Citing this family (113)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2001083740A2 (en) 2000-05-04 2001-11-08 Avi Biopharma, Inc. Splice-region antisense composition and method
EP1629105B1 (en) 2003-04-29 2010-09-01 AVI BioPharma, Inc. Compositions for enhancing transport and antisense efficacy of nucleic acid analog into cells
US20050222068A1 (en) * 2003-10-23 2005-10-06 Mourich Dan V Method and antisense composition for selective inhibition of HIV infection in hematopoietic cells
US20050171044A1 (en) * 2003-12-24 2005-08-04 Stein David A. Oligonucleotide compound and method for treating nidovirus infections
EP1713332A4 (en) * 2004-01-23 2010-08-18 Avi Biopharma Inc ANTISENSE OLIGOMERS AND METHOD FOR INDUCTION OF IMMUNOTHERAPY AND IMMUNOSUPPRESSION
US20050288246A1 (en) 2004-05-24 2005-12-29 Iversen Patrick L Peptide conjugated, inosine-substituted antisense oligomer compound and method
HUE028632T2 (en) 2004-06-28 2016-12-28 Univ Western Australia To skip an antisense oligonucleotide exon and use it for procedures
SI1766012T1 (sl) 2004-07-02 2011-10-28 Avi Biopharma Inc Protismiselni antibakterijski postopek in spojina
US8129352B2 (en) 2004-09-16 2012-03-06 Avi Biopharma, Inc. Antisense antiviral compound and method for treating ssRNA viral infection
US7524829B2 (en) * 2004-11-01 2009-04-28 Avi Biopharma, Inc. Antisense antiviral compounds and methods for treating a filovirus infection
CA2596506C (en) * 2005-02-09 2021-04-06 Avi Biopharma, Inc. Antisense composition and method for treating muscle atrophy
US8067571B2 (en) 2005-07-13 2011-11-29 Avi Biopharma, Inc. Antibacterial antisense oligonucleotide and method
WO2007030691A2 (en) * 2005-09-08 2007-03-15 Avi Biopharma, Inc. Antisense antiviral compound and method for treating picornavirus infection
US8501704B2 (en) 2005-11-08 2013-08-06 Sarepta Therapeutics, Inc. Immunosuppression compound and treatment method
US8785407B2 (en) * 2006-05-10 2014-07-22 Sarepta Therapeutics, Inc. Antisense antiviral agent and method for treating ssRNA viral infection
US20070265215A1 (en) * 2006-05-11 2007-11-15 Iversen Patrick L Antisense restenosis composition and method
EP2170363B1 (en) * 2007-06-29 2018-08-08 Sarepta Therapeutics, Inc. Tissue specific peptide conjugates and methods
AU2015200600B2 (en) * 2007-06-29 2017-04-20 Sarepta Therapeutics, Inc. Tissue specific peptide conjugates and methods
US20100016215A1 (en) 2007-06-29 2010-01-21 Avi Biopharma, Inc. Compound and method for treating myotonic dystrophy
JP5515738B2 (ja) * 2007-07-25 2014-06-11 味の素株式会社 ジベンゾフルベン誘導体の淘汰方法
US8076476B2 (en) * 2007-11-15 2011-12-13 Avi Biopharma, Inc. Synthesis of morpholino oligomers using doubly protected guanine morpholino subunits
US8299206B2 (en) * 2007-11-15 2012-10-30 Avi Biopharma, Inc. Method of synthesis of morpholino oligomers
KR101617472B1 (ko) * 2007-11-15 2016-05-02 사렙타 쎄러퓨틱스 인코퍼레이티드 모르폴리노 올리고머의 합성 방법
WO2009086469A2 (en) * 2007-12-28 2009-07-09 Avi Biopharma, Inc. Immunomodulatory agents and methods of use
DK3133160T3 (da) 2008-10-24 2019-04-01 Sarepta Therapeutics Inc Exon-overspringssammensætninger til dmd
CA2746508A1 (en) * 2008-12-17 2010-07-15 Avi Biopharma, Inc. Antisense compositions and methods for modulating contact hypersensitivity or contact dermatitis
US9200276B2 (en) 2009-06-01 2015-12-01 Halo-Bio Rnai Therapeutics, Inc. Polynucleotides for multivalent RNA interference, compositions and methods of use thereof
US20110269665A1 (en) 2009-06-26 2011-11-03 Avi Biopharma, Inc. Compound and method for treating myotonic dystrophy
WO2011018798A2 (en) * 2009-08-14 2011-02-17 Indian Association For The Cultivation Of Science Morpholino-based antisense agent
CA2770888C (en) * 2009-08-31 2020-04-14 Gen-Probe Incorporated Dengue virus assay
KR102239374B1 (ko) 2009-11-12 2021-04-14 더 유니버시티 오브 웨스턴 오스트레일리아 안티센스 분자 및 이를 이용한 질환 치료방법
KR101944119B1 (ko) 2009-11-13 2019-01-30 사렙타 쎄러퓨틱스 인코퍼레이티드 안티센스 항바이러스 화합물 및 인플루엔자 바이러스 감염을 치료하는 방법
EP3214174B1 (en) 2010-03-04 2019-10-16 InteRNA Technologies B.V. A mirna molecule defined by its source and its diagnostic and therapeutic uses in diseases or conditions associated with emt
WO2011113015A2 (en) * 2010-03-12 2011-09-15 Avi Biopharma, Inc. Antisense modulation of nuclear hormone receptors
US9238042B2 (en) 2010-05-13 2016-01-19 Sarepta Therapeutics, Inc. Antisense modulation of interleukins 17 and 23 signaling
AU2013202731B2 (en) * 2010-05-28 2016-04-21 Sarepta Therapeutics, Inc. Oligonucleotide analogues having modified intersubunit linkages and/or terminal groups
JP2013530154A (ja) * 2010-05-28 2013-07-25 サレプタ セラピューティクス， インコーポレイテッド 修飾されたサブユニット間結合および／または末端基を有するオリゴヌクレオチドアナログ
NZ704322A (en) 2010-07-06 2016-07-29 Interna Technologies Bv Mirna and its diagnostic and therapeutic uses in diseases or conditions associated with melanoma, or in diseases or conditions associated with activated braf pathway
US8198429B2 (en) 2010-08-09 2012-06-12 Avi Biopharma, Inc. Antisense antiviral compounds and methods for treating a filovirus infection
TWI541024B (zh) * 2010-09-01 2016-07-11 日本新藥股份有限公司 反義核酸
US10017763B2 (en) 2010-09-03 2018-07-10 Sarepta Therapeutics, Inc. dsRNA molecules comprising oligonucleotide analogs having modified intersubunit linkages and/or terminal groups
PT2623507T (pt) * 2010-09-30 2016-12-23 Nippon Shinyaku Co Ltd Derivado de ácido morfolino-nucleico
EP2474617A1 (en) 2011-01-11 2012-07-11 InteRNA Technologies BV Mir for treating neo-angiogenesis
WO2012100156A1 (en) 2011-01-20 2012-07-26 Hercules Incorporated Enhanced dry strength and drainage performance by combining glyoxalated acrylamide-containing polymers with cationic aqueous dispersion polymers
US9161948B2 (en) 2011-05-05 2015-10-20 Sarepta Therapeutics, Inc. Peptide oligonucleotide conjugates
AU2011367230B2 (en) 2011-05-05 2017-08-10 Sarepta Therapeutics, Inc. Peptide oligonucleotide conjugates
US10100305B2 (en) 2011-07-15 2018-10-16 Sarepta Therapeutics, Inc. Methods and compositions for manipulating translation of protein isoforms from alternative initiation of start sites
US20130085139A1 (en) 2011-10-04 2013-04-04 Royal Holloway And Bedford New College Oligomers
EA035030B1 (ru) * 2011-11-18 2020-04-20 Сарепта Терапьютикс, Инк. Модифицированные морфолиновые аналоги олигонуклеотидов
JP6496549B2 (ja) * 2011-11-30 2019-04-03 サレプタ セラピューティクス， インコーポレイテッド 脊髄性筋萎縮症における誘発されたエクソン包含
US10066228B2 (en) 2011-11-30 2018-09-04 Sarepta Therapeutics, Inc. Oligonucleotides for treating expanded repeat diseases
DK2788487T3 (da) 2011-12-08 2018-07-23 Sarepta Therapeutics Inc Oligonukleotidanaloger målrettet mod human lmna
EP3369818B1 (en) 2011-12-22 2021-06-09 InteRNA Technologies B.V. Mirna for treating head and neck cancer
EA031110B1 (ru) 2012-03-20 2018-11-30 Сарепта Терапьютикс, Инк. Конъюгаты бороновых кислот олигонуклеотидных аналогов
JP6404219B2 (ja) 2012-09-25 2018-10-10 ジェンザイム・コーポレーション 筋強直性ジストロフィーを治療するためのペプチド結合モルホリノアンチセンスオリゴヌクレオチド
EP2917348A1 (en) 2012-11-06 2015-09-16 InteRNA Technologies B.V. Combination for use in treating diseases or conditions associated with melanoma, or treating diseases or conditions associated with activated b-raf pathway
CN106414739A (zh) 2012-12-20 2017-02-15 萨雷普塔医疗公司 用于治疗肌营养不良症的改良的外显子跳跃组合物
CN103060325B (zh) * 2013-01-14 2015-01-07 韩健宝 抗猪流行性腹泻病毒pedv的反义核酸及肽核酸pna
CA2906209A1 (en) 2013-03-14 2014-09-25 Sarepta Therapeutics, Inc. Exon skipping compositions for treating muscular dystrophy targeting the annealing site h44a (-07+15)
US20160040162A1 (en) 2013-03-14 2016-02-11 Sarepta Therapeutics, Inc. Exon skipping compositions for treating muscular dystrophy
US9506058B2 (en) 2013-03-15 2016-11-29 Sarepta Therapeutics, Inc. Compositions for treating muscular dystrophy
KR20210088009A (ko) 2013-09-05 2021-07-13 사렙타 쎄러퓨틱스, 인코퍼레이티드 산성 알파-글루코시다제 내 안티센스-유도된 엑손2 포함
EP3480312A1 (en) 2013-09-11 2019-05-08 Synthena AG Nucleic acids and methods for the treatment of pompe disease
TWI713450B (zh) 2014-05-23 2020-12-21 美商健臻公司 藉由使用反義寡核苷酸創造提前終止密碼子抑制或下調肝醣合成酶
JP6673211B2 (ja) * 2014-10-14 2020-03-25 味の素株式会社 モルフォリノオリゴヌクレオチドの製造方法
MA41795A (fr) * 2015-03-18 2018-01-23 Sarepta Therapeutics Inc Exclusion d'un exon induite par des composés antisens dans la myostatine
MA50829A (fr) 2015-06-01 2018-04-11 Sarepta Therapeutics Inc Exclusion d'exon induite pat technologie antisens dans le collagène de type vii
EP3302489A4 (en) 2015-06-04 2019-02-06 Sarepta Therapeutics, Inc. METHOD AND COMPOUNDS FOR THE TREATMENT OF DISEASES AND SUFFERING IN CONNECTION WITH LYMPHOCYTES
WO2017035278A1 (en) 2015-08-24 2017-03-02 Halo-Bio Rnai Therapeutics, Inc. Polynucleotide nanoparticles for the modulation of gene expression and uses thereof
CA2996164A1 (en) 2015-08-28 2017-03-09 Sarepta Therapeutics, Inc. Modified antisense oligomers for exon inclusion in spinal muscular atrophy
EA201890811A1 (ru) 2015-09-30 2018-09-28 Сарепта Терапьютикс, Инк. Способы лечения мышечной дистрофии
MA45819A (fr) 2015-10-09 2018-08-15 Sarepta Therapeutics Inc Compositions et méthodes pour traiter la dystrophie musculaire de duchenne et troubles associés
MA45328A (fr) 2016-04-01 2019-02-06 Avidity Biosciences Llc Compositions acide nucléique-polypeptide et utilisations de celles-ci
KR102522059B1 (ko) 2016-04-18 2023-04-14 사렙타 쎄러퓨틱스 인코퍼레이티드 안티센스 올리고머, 및 산성 알파-글루코시다제 유전자와 연관된 질환을 치료하기 위한 이의 사용 방법
EA201892467A1 (ru) 2016-04-29 2019-05-31 Сарепта Терапьютикс, Инк. Олигонуклеотидные аналоги, нацеленные на lmna человека
EP3564248A1 (en) * 2016-05-24 2019-11-06 Sarepta Therapeutics, Inc. Processes for preparing phosphorodiamidate morpholino oligomers
JP2019534862A (ja) * 2016-09-20 2019-12-05 ザ リージェンツ オブ ザ ユニヴァーシティ オブ コロラド，ア ボディ コーポレイト ホスホルアミダイト化学を使用する骨格修飾モルホリノオリゴヌクレオチド及びキメラの合成
KR102552428B1 (ko) 2016-12-19 2023-07-06 사렙타 쎄러퓨틱스 인코퍼레이티드 근육 이상증에 대한 엑손 스킵핑 올리고머 결합체
CA3049424A1 (en) 2017-01-06 2018-07-12 Avidity Biosciences Llc Nucleic acid-polypeptide compositions and methods of inducing exon skipping
EP3593144A1 (en) 2017-03-10 2020-01-15 UCL Business Ltd Method relating to myostatin pathway inhibition
SG10201705285SA (en) * 2017-06-27 2019-01-30 Agency Science Tech & Res Antisense oligonucleotides
GB201711809D0 (en) 2017-07-21 2017-09-06 Governors Of The Univ Of Alberta Antisense oligonucleotide
MA49986A (fr) * 2017-09-25 2020-07-01 Massachusetts Inst Technology Procédés de préparation d'oligomères morpholino phosphorodiamidate par l'intermédiaire d'une synthèse à flux rapide
KR20200060496A (ko) 2017-10-04 2020-05-29 어비디티 바이오사이언시스 인크. 핵산-폴리펩티드 조성물 및 그의 용도
WO2019079367A1 (en) * 2017-10-17 2019-04-25 Sarepta Therapeutics, Inc. OLIGONUCLEOTIDE CONJUGATES-BICYCLIC PEPTIDES
MA50834A (fr) * 2017-10-17 2020-08-26 Massachusetts Inst Technology Peptides de pénétration cellulaire pour administration antisens
US11555189B2 (en) 2017-10-18 2023-01-17 Sarepta Therapeutics, Inc. Antisense oligomer compounds
CA3079524A1 (en) 2017-11-03 2019-05-09 Interna Technologies B.V. Mirna molecule, equivalent, antagomir, or source thereof for treating and/or diagnosing a condition and/or a disease associated with neuronal deficiency or for neuronal (re)generation
WO2019113393A1 (en) 2017-12-06 2019-06-13 Avidity Biosciences Llc Compositions and methods of treating muscle atrophy and myotonic dystrophy
JP2021513508A (ja) 2018-02-12 2021-05-27 インテアールエヌエー テクノロジーズ ビー．ヴイ．ＩｎｔｅＲＮＡ Ｔｅｃｈｎｏｌｏｇｉｅｓ Ｂ．Ｖ． 抗がんマイクロｒｎａ及びその脂質製剤
US20210260206A1 (en) * 2018-03-16 2021-08-26 Sarepta Therapeutics, Inc. Chimeric peptides for antisense deliver
SG11202011094PA (en) * 2018-05-10 2020-12-30 Nippon Shinyaku Co Ltd Method for preparing oligonucleic acid compound
MX2021007368A (es) 2018-12-21 2021-07-15 Avidity Biosciences Inc Anticuerpos anti-receptor de transferrina y usos de los mismos.
GB201821269D0 (en) 2018-12-28 2019-02-13 Nippon Shinyaku Co Ltd Myostatin signal inhibitor
WO2020157760A1 (en) 2019-01-31 2020-08-06 Bar Ilan University Neoantigens created by aberrant-induced splicing and uses thereof in enhancing immunotherapy
CA3142283A1 (en) 2019-06-06 2020-12-10 Avidity Biosciences, Inc. Nucleic acid-polypeptide compositions and uses thereof
EP3987029A1 (en) 2019-06-19 2022-04-27 Sarepta Therapeutics, Inc. Methods for treating muscular dystrophy
US20230073008A1 (en) 2019-12-26 2023-03-09 Nippon Shinyaku Co., Ltd. Antisense nucleic acid that induces skipping of exon 50
KR20220145865A (ko) 2020-02-28 2022-10-31 니뽄 신야쿠 가부시키가이샤 엑손 51의 스키핑을 유도하는 안티센스 핵산
AU2021237465A1 (en) 2020-03-19 2022-10-13 Avidity Biosciences, Inc. Compositions and methods of treating Facioscapulohumeral muscular dystrophy
KR20220161378A (ko) 2020-03-27 2022-12-06 어비디티 바이오사이언시스 인크. 근이영양증의 치료용 조성물 및 방법
CN111575409B (zh) * 2020-05-23 2023-04-18 黑龙江八一农垦大学 基于整合素配体识别肽抑制猪流行性腹泻病毒感染的研究方法
WO2022106695A1 (en) 2020-11-23 2022-05-27 Alpha Anomeric Sas Nucleic acid duplexes
IL309626A (en) 2021-06-23 2024-02-01 Nippon Shinyaku Co Ltd A combination of antisense oligomers
KR20240035503A (ko) 2021-07-08 2024-03-15 니뽄 신야쿠 가부시키가이샤 석출 억제제
WO2023282345A1 (ja) 2021-07-08 2023-01-12 日本新薬株式会社 腎毒性軽減剤
JPWO2023282344A1 (da) 2021-07-08 2023-01-12
WO2023034515A2 (en) 2021-09-03 2023-03-09 Sarepta Therapeutics, Inc. Delivery of anitsense oligomers by mirror image peptides
AU2022345098A1 (en) 2021-09-16 2024-04-04 Avidity Biosciences, Inc. Compositions and methods of treating facioscapulohumeral muscular dystrophy
CA3233242A1 (en) 2021-09-30 2023-04-06 Sarepta Therapeutics, Inc. Antisense oligonucleotides having one or more abasic units
WO2023070086A1 (en) 2021-10-22 2023-04-27 Sarepta Therapeutics, Inc. Morpholino oligomers for treatment of peripheral myelin protein 22 related diseases
WO2023205451A1 (en) 2022-04-22 2023-10-26 Entrada Therapeutics, Inc. Cyclic peptides for delivering therapeutics
WO2024064237A2 (en) 2022-09-21 2024-03-28 Sarepta Therapeutics, Inc. Dmd antisense oligonucleotide-mediated exon skipping efficiency

Family Cites Families (53)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5185444A (en) 1985-03-15 1993-02-09 Anti-Gene Deveopment Group Uncharged morpolino-based polymers having phosphorous containing chiral intersubunit linkages
US5034506A (en) 1985-03-15 1991-07-23 Anti-Gene Development Group Uncharged morpholino-based polymers having achiral intersubunit linkages
US5217866A (en) 1985-03-15 1993-06-08 Anti-Gene Development Group Polynucleotide assay reagent and method
US5506337A (en) 1985-03-15 1996-04-09 Antivirals Inc. Morpholino-subunit combinatorial library and method
US5521063A (en) 1985-03-15 1996-05-28 Antivirals Inc. Polynucleotide reagent containing chiral subunits and methods of use
US5166315A (en) 1989-12-20 1992-11-24 Anti-Gene Development Group Sequence-specific binding polymers for duplex nucleic acids
ATE81872T1 (de) 1985-03-15 1992-11-15 James Summerton Stereoregulare polynukleotiden bindende polymere.
AU655164B2 (en) * 1989-12-20 1994-12-08 Antivirals Inc. Uncharged morpholino-based polymers having phosphorous-containing chiral intersubunit linkages
US5852188A (en) 1990-01-11 1998-12-22 Isis Pharmaceuticals, Inc. Oligonucleotides having chiral phosphorus linkages
CA2089562A1 (en) 1990-08-14 1992-02-15 Lex M. Cowsert Inhibition of influenza virus type a, ann arbor strain h2n2 by antisense oligonucleotides
JPH07501204A (ja) 1991-06-28 1995-02-09 マサチューセッツ インスティテュート オブ テクノロジー 局所的オリゴヌクレオチド療法
US5576302A (en) 1991-10-15 1996-11-19 Isis Pharmaceuticals, Inc. Oligonucleotides for modulating hepatitis C virus having phosphorothioate linkages of high chiral purity
EP0672175A4 (en) 1991-12-23 1997-08-06 Chiron Corp HAV PROBES USED IN SOLUTION PHASE SANDWICH HYBRIDIZATION METHODS.
US6174868B1 (en) 1992-09-10 2001-01-16 Isis Pharmaceuticals, Inc. Compositions and methods for treatment of hepatitis C virus-associated diseases
US5801154A (en) 1993-10-18 1998-09-01 Isis Pharmaceuticals, Inc. Antisense oligonucleotide modulation of multidrug resistance-associated protein
US6060456A (en) 1993-11-16 2000-05-09 Genta Incorporated Chimeric oligonucleoside compounds
US5734039A (en) 1994-09-15 1998-03-31 Thomas Jefferson University Antisense oligonucleotides targeting cooperating oncogenes
GB9510718D0 (en) 1995-05-26 1995-07-19 Sod Conseils Rech Applic Antisense oligonucleotides
US5955318A (en) 1995-08-14 1999-09-21 Abbott Laboratories Reagents and methods useful for controlling the translation of hepatitis GBV proteins
US6686338B1 (en) 1996-02-23 2004-02-03 The Board Of Regents Of The University Of Nebraska Enzyme inhibitors for metabolic redirection
US6245747B1 (en) 1996-03-12 2001-06-12 The Board Of Regents Of The University Of Nebraska Targeted site specific antisense oligodeoxynucleotide delivery method
PL337033A1 (en) 1997-05-21 2000-07-31 Univ Leland Stanford Junior Composition for and methods of enhancing transport through permeable biological membranes
AUPP398498A0 (en) 1998-06-09 1998-07-02 Silverbrook Research Pty Ltd A method of manufacture of an image creation apparatus (ijm44)
US6133246A (en) 1997-08-13 2000-10-17 Isis Pharmaceuticals Inc. Antisense oligonucleotide compositions and methods for the modulation of JNK proteins
US6228579B1 (en) 1997-11-14 2001-05-08 San Diego State University Foundation Method for identifying microbial proliferation genes
WO2000002588A1 (en) 1998-07-13 2000-01-20 The Board Of Regents Of The University Of Nebraska Targeted site specific drug delivery compositions and method of use
US7094765B1 (en) 1999-01-29 2006-08-22 Avi Biopharma, Inc. Antisense restenosis composition and method
EP1173561A2 (en) 1999-01-29 2002-01-23 Avi Biopharma, Inc. Non-invasive method for detecting target rna
US20030095953A1 (en) 1999-11-12 2003-05-22 Myles C. Cabot Methods of reversing drug resistance in cancer cells
EP1238071B1 (en) 1999-11-29 2008-04-23 Avi Biopharma, Inc. Uncharged antisense oligonucleotides targeted to bacterial 16s and 23s rrnas and their uses
EP1248813A2 (en) 2000-01-04 2002-10-16 Avi Biopharma, Inc. Antisense antibacterial cell division composition and method
WO2001083740A2 (en) 2000-05-04 2001-11-08 Avi Biopharma, Inc. Splice-region antisense composition and method
AU2001263197B2 (en) 2000-05-17 2006-11-09 The Board Of Regents Of The University Of Nebraska Antisense enzyme inhibitors for metabolic redirection
EP1301525B1 (en) 2000-07-06 2015-09-02 Sarepta Therapeutics, Inc. Transforming growth factor beta (tgf-beta) blocking agent-treated stem cell composition and method
KR20040004629A (ko) * 2001-05-17 2004-01-13 에이브이아이 바이오파마 인코포레이티드 ｃ-ｍｙｃ 안티센스 올리고머를 사용한 암치료를 위한조합 접근법
US20030224353A1 (en) 2001-10-16 2003-12-04 Stein David A. Antisense antiviral agent and method for treating ssRNA viral infection
CN100547071C (zh) 2001-10-16 2009-10-07 Avi生物制药公司 用于治疗单链rna病毒感染的抗病毒反义核酸的试剂和方法
US20030207907A1 (en) 2002-05-03 2003-11-06 Iversen Patrick L. Delivery of microparticle-conjugated drugs for inhibition of stenosis
BR0314236A (pt) 2002-09-13 2005-08-09 Replicor Inc Formulação de oligonucleotìdeo, composição farmacêutica, kit, composto antiviral, preparação de oligonucleotìdeo e métodos para seleção de um oligonucleotìdeo antiviral para uso como um agente antiviral, para profilaxia ou tratamento de uma infecção viral em um paciente, para tratamento profilático de câncer causado por oncovìrus, para identificação de um composto que altera a ligação de um oligonucleotìdeo a pelo menos um componente viral, para purificação da ligação de oligonucleotìdeos a pelo menos um componente viral e para enriquecimento de oligonucleotìdeos a partir de um agrupamento de oligonucleotìdeos
EP2977470B1 (en) 2002-10-16 2018-01-03 Gen-Probe Incorporated Compositions and methods for detecting west nile virus
EP1585755B1 (en) 2002-12-31 2015-08-05 Sigma-Aldrich Co. LLC Methods and compositions for the tandem synthesis of two or more oligonuleotides on the same solid support
CA2533218C (en) 2003-08-05 2014-11-18 Avi Biopharma, Inc. Oligonucleotide analog and method for treating flavivirus infections
US20050171044A1 (en) 2003-12-24 2005-08-04 Stein David A. Oligonucleotide compound and method for treating nidovirus infections
EP1713332A4 (en) 2004-01-23 2010-08-18 Avi Biopharma Inc ANTISENSE OLIGOMERS AND METHOD FOR INDUCTION OF IMMUNOTHERAPY AND IMMUNOSUPPRESSION
US20050288246A1 (en) * 2004-05-24 2005-12-29 Iversen Patrick L Peptide conjugated, inosine-substituted antisense oligomer compound and method
SI1766012T1 (sl) 2004-07-02 2011-10-28 Avi Biopharma Inc Protismiselni antibakterijski postopek in spojina
US8129352B2 (en) 2004-09-16 2012-03-06 Avi Biopharma, Inc. Antisense antiviral compound and method for treating ssRNA viral infection
US8357664B2 (en) * 2004-10-26 2013-01-22 Avi Biopharma, Inc. Antisense antiviral compound and method for treating influenza viral infection
US7524829B2 (en) * 2004-11-01 2009-04-28 Avi Biopharma, Inc. Antisense antiviral compounds and methods for treating a filovirus infection
TW200622777A (en) * 2004-12-31 2006-07-01 Inventec Corp Manufacturing-order giving system and method thereof
WO2007030576A2 (en) 2005-09-08 2007-03-15 Avi Biopharma, Inc. Antisense antiviral compound and method for treating picornavirus infection
WO2007030691A2 (en) 2005-09-08 2007-03-15 Avi Biopharma, Inc. Antisense antiviral compound and method for treating picornavirus infection
US8785407B2 (en) 2006-05-10 2014-07-22 Sarepta Therapeutics, Inc. Antisense antiviral agent and method for treating ssRNA viral infection

Also Published As

Publication number Publication date
PT2735568T (pt) 2017-11-14
LT2024499T (lt) 2018-02-26
EP2735568B1 (en) 2017-08-02
AU2007297861A1 (en) 2008-03-27
DK2024499T3 (da) 2018-01-29
US7943762B2 (en) 2011-05-17
US20090088562A1 (en) 2009-04-02
WO2008036127A2 (en) 2008-03-27
EP2735568B8 (en) 2017-09-27
WO2008036127A3 (en) 2008-11-20
EP2024499A2 (en) 2009-02-18
JP2010505741A (ja) 2010-02-25
EP2024499B1 (en) 2017-10-25
EP2735568A1 (en) 2014-05-28
HUE035799T2 (en) 2018-05-28
HK1198388A1 (en) 2015-04-17
CY1120486T1 (el) 2019-07-10
CY1120409T1 (el) 2019-07-10
ES2657400T3 (es) 2018-03-05
SI2735568T1 (en) 2018-01-31
LT2735568T (lt) 2017-11-27
ES2645410T3 (es) 2017-12-05
CA2651881A1 (en) 2008-03-27
PL2735568T3 (pl) 2018-02-28
SI2024499T1 (en) 2018-04-30
HUE036995T2 (hu) 2018-08-28

Similar Documents

Publication Publication Date Title
DK2735568T3 (da) Oligonukleotidanaloger med kationiske bindinger mellem underenheder
BRPI0718796A2 (pt) Nucleotídeo
FI20065288A0 (fi) Autentikointi
EP1988750A4 (en) PLANAR HEATER
BRPI0815725A2 (pt) Métodos para detecção de oligonucleotídeos
EP1982167A4 (en) BIOSENSOR
EP2114396A4 (en) METHOD FOR IMPROVING TRAINING PERFORMANCE
ATE510923T1 (de) Nukleinsäure
NO20061669L (no) SmartPlug with centralizer means
DE502007005526D1 (de) Pipettiervorrichtung
DE502006006067D1 (de) Ng
ATE410929T1 (de) Verbessertes getränk
EP2017608A4 (en) BIOSENSOR
IL173251A0 (en) Multi purpose probe
EP2008588A4 (en) BIOSENSOR CHIP
EP2017607A4 (en) BIOSENSOR
GB0622181D0 (en) Arginase
GB0611114D0 (en) Analysis technique
GB2444770B (en) Horse boot
EP2047267A4 (en) BIOSENSOR
DE112007003228A5 (de) Temperiervorrichtung
ES1062859Y (es) Salvamanteles
AT504183A3 (de) Skibindungssystem
FIU20060064U0 (fi) Kaksinieluinen katiska
AU3782P (en) Sierrich Prunus persica